A Chinese medicine formula(Sanzi-huangshi pill) as an adjuvant therapy for lower-risk myelodysplastic syndrome: protocol for a prospective, randomized, open-label, blinded-endpoint (PROBE) trial

Author:

Xu Hao1,Hu Qi1,Tao Yuchen1,Cai Shuyang1,Wang Yanlu1,Hu Kexin1,Xue Tingting1,Bao Jizhang1,Lu Jiahui1

Affiliation:

1. Shanghai Municipal Hospital of Traditional Chinese Medicine

Abstract

Abstract Background: Lower-risk myelodysplastic syndrome (MDS) is characterized by the presence of dysplasia, low bone marrow blast percentage, low number and depth of cytopenia(s), and relatively good-risk karyotpic and molecular abnormalities. Lower-risk MDS patients have primarily received supportive care, immunomodulators, and immunosuppressants. New effective regimens or drugs are urgently needed for the treatment of lower-risk MDS owing to the unsatisfactory clinical efficacy. Sanzi-huangshi pill is an arsenic-containing Chinese medicine that has been used as a promising drug for MDS for decades, but its efficacy has not yet been proven by high-quality clinical trial. Methods: SPIRIT guidelines were followed in drafting this protocol for a randomized controlled multicenter trial. Ninety-two adults with lower-risk MDS are randomly assigned in a 1:1 ratio to Sanzi-huangshi pill group or control group, and all participants are required to receive 6 months of intervention and 18 months of observation. The primary outcome is Overall Response Rate defined as the sum of complete remission, partial remission, cytogenetic complete remission and hematologic improvement accounting for the proportion of total evaluable cases. Discussion: This is the first randomized controlled trial to evaluate the efficacy and safety of arsenic-containing Chinese medicine as an adjuvant therapy in lower-risk MDS with serum erythropoietin (sEPO) >500 IU/ml. The purpose of this study is to correctly evaluate the position of traditional Chinese medicine in the treatment plan of MDS and to formulate an effective regimen of integrated Traditional Chinese and Western Medicine to provide preliminary clinical evidence. Clinical Trial Registration: http://www.chictr.org.cn, identifier: ChiCTR2200064230, Registered September 30, 2022.

Publisher

Research Square Platform LLC

Reference25 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber DA;Blood,2016

2. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it;Zeidan AM;BLOOD REV,2019

3. First report of incidence of adult myelodysplastic syndrome in China;Wang W;ANN HEMATOL,2012

4. Myelodysplastic Syndromes;Cazzola M;N Engl J Med,2020

5. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg P;Blood,1997

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3